Josh Hawley Grills Pharma CEO on Prescription Drug Prices and PBM Practices

PBMs' Role in Drug Pricing

• 💊 Pharmacy Benefit Managers (PBMs) are presented as entities meant to help employers and plan sponsors administer benefits at a more affordable point for consumers.
• 🎯 However, Senator Hawley argues that PBMs are not succeeding in making drugs cheaper for patients, citing data that Americans pay significantly more for brand-name drugs compared to other countries.
• 📈 PBM CEO Juan Carlos Scott claims success in managing net costs but acknowledges the challenge of escalating drug company list prices.

Consumer Impact and PBM Profits

• ⚠️ Hawley asserts that patients are paying more for drugs overseas and that benefit designs favor insurance companies and PBMs, not patients.
• 💰 An FTC report is cited, indicating that the top three PBM companies generated $7.3 billion in profits between 2017 and 2022, raising questions about why drugs remain unaffordable.
• 💔 The transcript highlights that people in Missouri cannot afford insulin and other basic drugs, even with insurance plans managed by PBMs.

Competition and Market Consolidation

• 🤝 Scott suggests that more competition among drug companies through patent reforms could help address costs.
• 🚫 Hawley questions the need to break up the alliance between insurance companies and PBMs, noting that the largest PBMs are owned by the largest insurers, creating a consolidated industry.
• 🏥 The consolidation extends to PBMs also buying up pharmacies, leading to concerns about directing patients to owned pharmacies and creating out-of-network costs for those who don't comply.

Pharmacy Closures and Monopolistic Behavior

• 📉 In Missouri, 73 independent pharmacies closed in the past year, and two counties now have zero pharmacies, despite PBM profits.
• ⚖️ Hawley suggests this indicates classic monopolistic behavior and proposes breaking up PBMs, including a law preventing PBMs from owning pharmacies.
• 🚫 Scott opposes breaking up PBMs, citing market competition growth, which Hawley refutes by stating the biggest three PBMs control 80% of the business, leading to a lack of competition and a "racket" that harms patients.